Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-10-15

FDA Approved: IRBESARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved Lupin Pharmaceuticals' supplemental application for IRBESARTAN (irbesartan), indicating an approved change to the generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Irbesartan (irbesartan)

Snippet

SUPPL AP for IRBESARTAN (IRBESARTAN)